Shanghai Hile Bio-tech - Asset Resilience Ratio

Latest as of March 2026: 20.85%

Shanghai Hile Bio-tech (603718) has an Asset Resilience Ratio of 20.85% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 603718 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥260.45 Million

≈ $38.11 Million USD Cash + Short-term Investments

Total Assets

CN¥1.25 Billion

≈ $182.76 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Shanghai Hile Bio-tech's Asset Resilience Ratio has changed over time. See Shanghai Hile Bio-tech balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Hile Bio-tech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603718 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥260.45 Million	20.85%
Total Liquid Assets	CN¥260.45 Million	20.85%

Asset Resilience Insights

Good Liquidity Position: Shanghai Hile Bio-tech maintains a healthy 20.85% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Shanghai Hile Bio-tech Industry Peers by Asset Resilience Ratio

Compare Shanghai Hile Bio-tech's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Shanghai Hile Bio-tech (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Hile Bio-tech.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	18.74%	CN¥210.84 Million ≈ $30.85 Million	CN¥1.13 Billion ≈ $164.64 Million	+10.06pp
2024-12-31	8.68%	CN¥158.58 Million ≈ $23.21 Million	CN¥1.83 Billion ≈ $267.32 Million	-4.14pp
2023-12-31	12.82%	CN¥212.48 Million ≈ $31.09 Million	CN¥1.66 Billion ≈ $242.58 Million	-2.78pp
2022-12-31	15.60%	CN¥236.15 Million ≈ $34.56 Million	CN¥1.51 Billion ≈ $221.58 Million	-5.31pp
2021-12-31	20.91%	CN¥385.59 Million ≈ $56.42 Million	CN¥1.84 Billion ≈ $269.85 Million	-7.23pp
2020-12-31	28.14%	CN¥502.73 Million ≈ $73.57 Million	CN¥1.79 Billion ≈ $261.46 Million	-3.84pp
2019-12-31	31.98%	CN¥544.00 Million ≈ $79.60 Million	CN¥1.70 Billion ≈ $248.95 Million	+8.00pp
2018-12-31	23.98%	CN¥419.24 Million ≈ $61.35 Million	CN¥1.75 Billion ≈ $255.87 Million	-11.96pp
2017-12-31	35.94%	CN¥575.66 Million ≈ $84.24 Million	CN¥1.60 Billion ≈ $234.38 Million	+4.11pp
2016-12-31	31.83%	CN¥471.00 Million ≈ $68.92 Million	CN¥1.48 Billion ≈ $216.56 Million	+8.36pp
2015-12-31	23.46%	CN¥291.00 Million ≈ $42.58 Million	CN¥1.24 Billion ≈ $181.50 Million	--

pp = percentage points

About Shanghai Hile Bio-tech

SHG:603718 China Biotechnology

Market Cap

$274.74 Million

CN¥1.88 Billion CNY

Market Cap Rank

#15343 Global

#4512 in China

Share Price

CN¥2.88

Change (1 day)

-3.68%

52-Week Range

CN¥2.88 - CN¥7.67

All Time High

CN¥51.09